Abstract
To better understand the opportunities and implications to global health in applying knowledge of human genomic variation in emerging economies we conducted case studies in Mexico, Thailand, South Africa and India. Our findings are relevant to the field of genomics as it intersects with public health and is a potential source of economic development in the developing world.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
UN Millennium Project 2005 Task Force on Science, Technology, and Innovation. Innovation: Applying Knowledge in Development. [online], (2005).
Frew, S. E. et al. India's health biotech sector at a crossroads. Nature Biotechnol. 25, 403–417 (2007).
Frew, S. E. et al. Chinese health biotech and the billion-patient market. Nature Biotechnol. 26, 37–53 (2008).
Masum, H., Daar, A. D., Al-Bader, S., Shah, R. & Singer, P. A. Accelerating health product innovation in sub-Saharan Africa. Innovations: Technology, Governance, Globalization 2, 129–149 (2007).
Séguin, B., Hardy, B. J., Singer, P. A. & Daar, A. S. Genomic medicine and developing countries: creating a room of their own. Nature Rev. Genet. 9, 487–493 (2008).
Daar, A. S. & Singer, P. A. Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nature Rev. Genet. 6, 241–246 (2005).
World Health Organization. Genomics and World Health: Report of the Advisory Committee on Health Research. [online], (2002).
Acknowledgements
This project was funded by Genome Canada through the Ontario Genomics Institute. The McLaughlin–Rotman Centre for Global Health, Program on Life Sciences, Ethics and Policy is primarily supported by Genome Canada through the Ontario Genomics Institute, the Ontario Research Fund, and the Bill and Melinda Gates Foundation. Other matching partners are listed at The McLaughlin–Rotman Centre for Global Health web site. A.S.D. and P.A.S. are supported by the McLaughlin Centre for Molecular Medicine. P.A.S. is supported by a Canadian Institutes of Health Research Distinguished Investigator award.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The Genomics Institute of Singapore, the Mexican National Institute of Genomic Medicine, and the Indian Council of Medical Research provided in kind co-funding for this research. The groups we interviewed fact-checked the descriptions of their centres, as is customary in qualitative research, but did not influence the editorial content of this article.
Related links
Rights and permissions
About this article
Cite this article
Séguin, B., Hardy, BJ., Singer, P. et al. Human genomic variation initiatives in emerging economies and developing countries. Nat Rev Genet 9 (Suppl 1), S3–S4 (2008). https://doi.org/10.1038/nrg2439
Issue Date:
DOI: https://doi.org/10.1038/nrg2439
This article is cited by
-
From diversity to delivery: the case of the Indian Genome Variation initiative
Nature Reviews Genetics (2008)
-
South Africa: from species cradle to genomic applications
Nature Reviews Genetics (2008)
-
Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN)
Nature Reviews Genetics (2008)
-
Universal health care, genomic medicine and Thailand: investing in today and tomorrow
Nature Reviews Genetics (2008)
